# A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies

> **NCT01798745** · PHASE2 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** JNJ-54452840
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01798745
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study not required for development
- **Last updated:** 2014-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01798745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01798745, "A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01798745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*